These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 7968028)

  • 41. Molecular findings and antibiotic-resistance in an outbreak of Acinetobacter baumannii in an intensive care unit.
    Longo B; Pantosti A; Luzzi I; Tarasi A; Di Sora F; Gallo S; Placanica P; Monaco M; Dionisi AM; Volpe I; Montella F; Cassone A; Rezza G
    Ann Ist Super Sanita; 2007; 43(1):83-8. PubMed ID: 17536158
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic relatedness of clinical and environmental Acinetobacter baumanii isolates from an intensive care unit outbreak.
    Senok A; Garaween G; Raji A; Khubnani H; Kim Sing G; Shibl A
    J Infect Dev Ctries; 2015 Jul; 9(6):665-9. PubMed ID: 26142679
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
    Wang H; Guo P; Sun H; Wang H; Yang Q; Chen M; Xu Y; Zhu Y
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4022-8. PubMed ID: 17846127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam.
    Jellison TK; Mckinnon PS; Rybak MJ
    Pharmacotherapy; 2001 Feb; 21(2):142-8. PubMed ID: 11213849
    [TBL] [Abstract][Full Text] [Related]  

  • 45. OXA-Carbapenemases Present in Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates from Patients in Kurdistan Region, Iraq.
    Ganjo AR; Maghdid DM; Mansoor IY; Kok DJ; Severin JA; Verbrugh HA; Kreft D; Fatah MH; Alnakshabandi AA; Dlnya A; Hammerum AM; Ng K; Goessens W
    Microb Drug Resist; 2016 Dec; 22(8):627-637. PubMed ID: 27003287
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular epidemiology of Acinetobacter baumannii and Acinetobacter nosocomialis in Germany over a 5-year period (2005-2009).
    Schleicher X; Higgins PG; Wisplinghoff H; Körber-Irrgang B; Kresken M; Seifert H
    Clin Microbiol Infect; 2013 Aug; 19(8):737-42. PubMed ID: 23034071
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.
    Tripodi MF; Durante-Mangoni E; Fortunato R; Utili R; Zarrilli R
    Int J Antimicrob Agents; 2007 Dec; 30(6):537-40. PubMed ID: 17851050
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of clinical and microbiological efficacy of antibiotic regimens against Acinetobacter baumannii.
    Ackerman BH; Haith LR; Patton ML; Guilday RE; Reigart CL; Stair-Buchmann M
    J Burn Care Res; 2013; 34(4):403-12. PubMed ID: 23237825
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High prevalence of multidrug resistance and metallo-beta-lactamase (MβL) producing Acinetobacter baumannii isolated from patients in ICU wards, Hamadan, Iran.
    Safari M; Saidijam M; Bahador A; Jafari R; Alikhani MY
    J Res Health Sci; 2013 Sep; 13(2):162-7. PubMed ID: 24077474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Successful treatment of a patient with multidrug resistant Acinetobacter baumannii meningitis with high dose ampicillin-sulbactam].
    Sayin Kutlu S; Saçar S; Süzer T; Cevahir N; Okke D; Dirgen Caylak S; Turgut H
    Mikrobiyol Bul; 2008 Apr; 42(2):353-8. PubMed ID: 18697435
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characteristics of carbapenem-resistant Acinetobacter spp. other than Acinetobacter baumannii in South Korea.
    Park YK; Jung SI; Park KH; Kim SH; Ko KS
    Int J Antimicrob Agents; 2012 Jan; 39(1):81-5. PubMed ID: 21996405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Spread of a single clone Acinetobacter baumannii strain in an intensive care unit of a teaching hospital in Turkey.
    Güdücüoglu H; Durmaz R; Yaman G; Cizmeci Z; Berktas M; Durmaz B
    New Microbiol; 2005 Oct; 28(4):337-43. PubMed ID: 16386018
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam.
    Jiménez-Mejías ME; Pachón J; Becerril B; Palomino-Nicás J; Rodríguez-Cobacho A; Revuelta M
    Clin Infect Dis; 1997 May; 24(5):932-5. PubMed ID: 9142795
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial susceptibility pattern in nosocomial infections caused by Acinetobacter species in Asir Region, Saudi Arabia.
    Abdalla NM; Osman AA; Haimour WO; Sarhan MA; Mohammed MN; Zyad EM; Al-Ghtani AM
    Pak J Biol Sci; 2013 Mar; 16(6):275-80. PubMed ID: 24498790
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
    Lenhard JR; Thamlikitkul V; Silveira FP; Garonzik SM; Tao X; Forrest A; Soo Shin B; Kaye KS; Bulitta JB; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2017 May; 72(5):1415-1420. PubMed ID: 28333347
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam.
    Pachón-Ibáñez ME; Fernández-Cuenca F; Docobo-Pérez F; Pachón J; Pascual A
    J Antimicrob Chemother; 2006 Sep; 58(3):689-92. PubMed ID: 16870647
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Spread of a carbapenem- and colistin-resistant Acinetobacter baumannii ST2 clonal strain causing outbreaks in two Sicilian hospitals.
    Agodi A; Voulgari E; Barchitta M; Quattrocchi A; Bellocchi P; Poulou A; Santangelo C; Castiglione G; Giaquinta L; Romeo MA; Vrioni G; Tsakris A
    J Hosp Infect; 2014 Apr; 86(4):260-6. PubMed ID: 24680473
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia.
    Choi JY; Kim CO; Park YS; Yoon HJ; Shin SY; Kim YK; Kim MS; Kim YA; Song YG; Yong D; Lee K; Kim JM
    Yonsei Med J; 2006 Feb; 47(1):63-9. PubMed ID: 16502486
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification and characteristics of imipenem-resistant Acinetobacter baumannii in surgical wards in a Chinese university hospital.
    Wang D; Ma L; Wu Z; Li M; Li X; Zhang W; Chen K
    Infect Dis (Lond); 2015 Mar; 47(3):182-6. PubMed ID: 25622942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Investigation and control of an outbreak of imipenem-resistant Acinetobacter baumannii Infection in a Pediatric Intensive Care Unit.
    Hong KB; Oh HS; Song JS; Lim JH; Kang DK; Son IS; Park JD; Kim EC; Lee HJ; Choi EH
    Pediatr Infect Dis J; 2012 Jul; 31(7):685-90. PubMed ID: 22466324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.